MedTrace Logo

Study of STA-1 as an Add-on Treatment to Donepezil

NCT01255046 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2014-08-20

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of STA-1 vs placebo as an add-on treatment to donepezil in patients with mild to moderate Alzheimer's Disease (AD).

Conditions

  • Alzheimer Disease

Interventions

DRUG

Donepezil,

10mg/tab, 1 tab/day for 72 weeks

DRUG

STA-1

300mg/tab, 2 tab/tid for 72 weeks

DRUG

placebo

2 tab/tid for 72 weeks

Sponsors & Collaborators

  • Sinphar Pharmaceutical Co., Ltd

    lead OTHER

Principal Investigators

  • Giia-Sheun Peng, MD · Tri-Service General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01255046 on ClinicalTrials.gov